The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer

Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions